ahlam1399
07-28-2016, 05:19 PM
U.S. biotech Celgene raises forecast as profit beats Street
(Reuters) - U.S. biotech**logy company Celgene Corp reported a better-than-expected quarterly profit and raised its adjusted earnings forecast for 2016 due to higher demand for its key multiple myeloma drug, Revlimid.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_O1F1mK6Taw:x3kYxTD3NtM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_O1F1mK6Taw:x3kYxTD3NtM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/_O1F1mK6Taw
(Reuters) - U.S. biotech**logy company Celgene Corp reported a better-than-expected quarterly profit and raised its adjusted earnings forecast for 2016 due to higher demand for its key multiple myeloma drug, Revlimid.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_O1F1mK6Taw:x3kYxTD3NtM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_O1F1mK6Taw:x3kYxTD3NtM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:x3kYxTD3NtM:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/_O1F1mK6Taw